Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Risankizumab has been shown to be safe and effective for the treatment of psoriasis in numerous randomized clinical trials and real-life studies. Real-life data on treatment for up to 4 years are lacking.
Objectives: The present study aims to estimate the drug survival (DS), effectiveness, and safety of risankizumab over a period of 208 weeks (W).
Methods: We included all consecutive patients with psoriasis or psoriatic arthritis receiving at least 1 dose of risankizumab. Effectiveness was evaluated according to the achievement of PASI 100 and PASI 90. DS was evaluated by a Kaplan-Meyer curve.
Results: A total of 545 patients were included in the study. Mean PASI decreased from 14 at baseline to 0.5 at 208W. PASI100 showed an increasing response, which was achieved in 33% and 74% of patients at 16W and 208W, respectively. For PASI90 a similar trend was seen, with a peak at 208W of 81% patients achieving the outcome. The estimated DS at 208W was 87.2% in patients at risk. Bio-naïve patients showed a significantly faster response than bio-experienced patients. Obesity and difficult-to-treat involvement seem to slow the response, with patients with difficult-site involvement having a lower risk of drug interruption (HR 0.15, CI 0.07-0.31, p<0.001). Safety was good and only 5 patients interrupted the treatment for adverse events.
Conclusions: Our study confirms the good effectiveness and favorable safety of risankizumab in a real-world setting for up to four years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ced/llaf305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Photodynamic therapy for glioblastoma: a narrative review.
J Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDFClinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.
J Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.
Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFTargeting the tumor microenvironment in colorectal cancer: the effect of Rapamycin on angiogenesis, apoptosis, and STAT5A/TORC1 signaling.
Mol Biol Rep
September 2025
Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. The tumor microenvironment (TME), particularly the interactions between endothelial cells and cancer-associated fibroblasts (CAFs), plays a pivotal role in promoting tumor growth, angiogenesis, oxidative stress, and therapy resistance. The HUVEC-fibroblast co-culture model closely mimics stromal-endothelial interactions observed in CRC, enabling mechanistic insights not achievable in monocultures.
View Article and Find Full Text PDFFirst-line treatment options for metastatic urothelial carcinoma: balancing efficacy, safety, and individual values and preferences through shared decision making.
Int J Clin Oncol
September 2025
Department of Urology, University of Tsukuba Institute of Medicine, Tsukuba, Ibaraki, 305-8575, Japan.
Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.
View Article and Find Full Text PDF